Skip to main content
PMC home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1994 Dec;70(6):1161–1164. doi: 10.1038/bjc.1994.465

Comparison of granisetron alone and granisetron plus dexamethasone in the prophylaxis of cytotoxic-induced emesis.

J Carmichael 1, E M Bessell 1, A L Harris 1, A W Hutcheon 1, P J Dawes 1, S Daniels 1, E M Bessel 1
PMCID: PMC2033694  PMID: 7981069

Abstract

Two hundred and seventy-eight adult chemonaive patients, receiving moderately emetogenic chemotherapy were randomly allocated to receive either intravenous (i.v.) granisetron 3 mg plus i.v. dexamethasone 8 mg or i.v. granisetron 3 mg plus i.v. placebo dexamethasone prior to chemotherapy. Eight-two per cent of all patients recruited were female, and 91% of all patients consumed less than 10 units of alcohol per week, suggesting a study population with an increased risk of nausea and vomiting. In the first 24 h 85% of patients who received granisetron plus dexamethasone were complete responders compared with 75.9% of the patients receiving granisetron alone (P = 0.053). There were statistically significant improvements in complete response over 7 days (P = 0.029) and in the numbers of patients receiving rescue antiemetic (P = 0.0004). Toxicity was minimal with no significant differences between treatment groups. These results confirm the antiemetic activity of granisetron and show that it has an additive effect in combination with dexamethasone.

Full text

PDF

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Chevallier B. The control of acute cisplatin-induced emesis--a comparative study of granisetron and a combination regimen of high-dose metoclopramide and dexamethasone. Granisetron Study Group. Br J Cancer. 1993 Jul;68(1):176–180. doi: 10.1038/bjc.1993.309. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. De Mulder P. H., Seynaeve C., Vermorken J. B., van Liessum P. A., Mols-Jevdevic S., Allman E. L., Beranek P., Verweij J. Ondansetron compared with high-dose metoclopramide in prophylaxis of acute and delayed cisplatin-induced nausea and vomiting. A multicenter, randomized, double-blind, crossover study. Ann Intern Med. 1990 Dec 1;113(11):834–840. doi: 10.7326/0003-4819-113-11-834. [DOI] [PubMed] [Google Scholar]
  3. Jones A. L., Hill A. S., Soukop M., Hutcheon A. W., Cassidy J., Kaye S. B., Sikora K., Carney D. N., Cunningham D. Comparison of dexamethasone and ondansetron in the prophylaxis of emesis induced by moderately emetogenic chemotherapy. Lancet. 1991 Aug 24;338(8765):483–487. doi: 10.1016/0140-6736(91)90554-3. [DOI] [PubMed] [Google Scholar]
  4. Kaye S. B. Antiemetic therapy--where do we go from here? Ann Oncol. 1993 Jun;4(6):443–445. doi: 10.1093/oxfordjournals.annonc.a058547. [DOI] [PubMed] [Google Scholar]
  5. Kris M. G., Gralla R. J., Tyson L. B., Clark R. A., Cirrincione C., Groshen S. Controlling delayed vomiting: double-blind, randomized trial comparing placebo, dexamethasone alone, and metoclopramide plus dexamethasone in patients receiving cisplatin. J Clin Oncol. 1989 Jan;7(1):108–114. doi: 10.1200/JCO.1989.7.1.108. [DOI] [PubMed] [Google Scholar]
  6. Marty M. A comparative study of the use of granisetron, a selective 5-HT3 antagonist, versus a standard anti-emetic regimen of chlorpromazine plus dexamethasone in the treatment of cytostatic-induced emesis. The Granisetron Study Group. Eur J Cancer. 1990;26 (Suppl 1):S28–S32. [PubMed] [Google Scholar]
  7. Marty M. A comparison of granisetron as a single agent with conventional combination antiemetic therapies in the treatment of cytostatic-induced emesis. The Granisetron Study Group. Eur J Cancer. 1992;28A Suppl 1:S12–S16. doi: 10.1016/0959-8049(92)90630-k. [DOI] [PubMed] [Google Scholar]
  8. Moreno I., Rosell R., Abad A., Barnadas A., Carles J., Ribelles N., Solano V., Font A. Comparison of three protracted antiemetic regimens for the control of delayed emesis in cisplatin-treated patients. Eur J Cancer. 1992;28A(8-9):1344–1347. doi: 10.1016/0959-8049(92)90515-4. [DOI] [PubMed] [Google Scholar]
  9. Roila F., Tonato M., Basurto C., Canaletti R., Morsia D., Passalacqua R., DiCostanzo F., Donati D., Colombo N., Ballatori E. Antiemetic activity of two different high doses of metoclopramide in cisplatin-treated cancer patients: a randomized double-blind trial of the Italian Oncology Group for Clinical Research. Cancer Treat Rep. 1985 Dec;69(12):1353–1357. [PubMed] [Google Scholar]
  10. Roila F., Tonato M., Cognetti F., Cortesi E., Favalli G., Marangolo M., Amadori D., Bella M. A., Gramazio V., Donati D. Prevention of cisplatin-induced emesis: a double-blind multicenter randomized crossover study comparing ondansetron and ondansetron plus dexamethasone. J Clin Oncol. 1991 Apr;9(4):675–678. doi: 10.1200/JCO.1991.9.4.675. [DOI] [PubMed] [Google Scholar]
  11. Smyth J. F., Coleman R. E., Nicolson M., Gallmeier W. M., Leonard R. C., Cornbleet M. A., Allan S. G., Upadhyaya B. K., Bruntsch U. Does dexamethasone enhance control of acute cisplatin induced emesis by ondansetron? BMJ. 1991 Dec 7;303(6815):1423–1426. doi: 10.1136/bmj.303.6815.1423. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Walsh T. D. Antiemetic drug combinations in advanced cancer. Lancet. 1982 May 1;1(8279):1018–1018. doi: 10.1016/s0140-6736(82)92015-3. [DOI] [PubMed] [Google Scholar]
  13. de Bruijn K. M. Tropisetron. A review of the clinical experience. Drugs. 1992;43 (Suppl 3):11–22. doi: 10.2165/00003495-199200433-00005. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES